Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–29 of 5 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Unresectable Thyroid Gland Carcinoma Clear all

Terminated Phase 1 Interventional

Safety Study of MGD009 in B7-H3-expressing Tumors

NCT02628535

View directory record Official record

Conditions: Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma
Interventions: MGD009; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older

Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more

Source: ClinicalTrials.gov public record

Updated Feb 7, 2022 · Synced May 21, 2026, 10:15 PM EDT

Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604

View directory record Official record

Conditions: Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions: CEA RNA-pulsed DC cancer vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Durham, North Carolina

Source: ClinicalTrials.gov public record

Updated Feb 21, 2013 · Synced May 21, 2026, 10:15 PM EDT

Completed Phase 1 Interventional

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

NCT00667641

View directory record Official record

Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: bortezomib, paclitaxel; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Source: ClinicalTrials.gov public record

Updated May 9, 2011 · Synced May 21, 2026, 10:15 PM EDT

Completed Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

NCT00784303

View directory record Official record

Conditions: Thyroid Cancer
Interventions: Lenvatinib (DTC Cohort), Lenvatinib (MTC Cohort); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 23
States / cities: Little Rock, Arkansas • Los Angeles, California • Los Gatos, California + 20 more

Source: ClinicalTrials.gov public record

Updated Apr 21, 2020 · Synced May 21, 2026, 10:15 PM EDT

Completed Phase 1Phase 2 Interventional Results available

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

NCT01208051

View directory record Official record

Conditions: Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Hurthle Cell Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions: Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis, Lenalidomide; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 30
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 24 more

Source: ClinicalTrials.gov public record

Updated Jul 14, 2021 · Synced May 21, 2026, 10:15 PM EDT